G protein-coupled receptors (GPCRs) are a large group of receptors of great biological and clinical relevance. Despite this, the tools for a detailed analysis of ligand -GPCR interactions are limited. The aim of this paper was to demonstrate how ligand binding to GPCRs can be followed in real-time on living cells. This was conducted using two model systems, the radiolabeled porcine peptide YY (pPYY) interacting with transfected human Y2 receptor (hY2R) and the bombesin antagonist RM26 binding to the naturally expressed gastrin-releasing peptide receptor (GRPR). By following the interaction over time, the affinity and kinetic properties such as association and dissociation rate were obtained.
Introduction
G-protein coupled receptors (GPCRs) constitute a large class of receptors of great biological importance. Abnormal expression, regulation and function have been linked to many diseases, making them important targets in diagnostic and therapy. The receptors transduce extracellular signals through the membrane via a number of conformational changes, but despite clinical relevance the knowledge about their molecular mechanisms is limited [1, 2] .
There are several methods to identify compounds that target GPCRs. Ligand-receptor binding assays, such as saturation assays, are widely used methods to determine the ligand-receptor affinity. Other strategies include indirect signaling assays, where binding to GPCRs is instead monitored by following the activity of the downstream signaling pathway. Although much information can be gained from such assays, a general drawback is that the downstream effect will depend on other components present in the cell, making it difficult to generalize results [3, 4] . Furthermore, both saturation assays and activity assays are most often end-point measurements, which typically rely on equilibrium being reached during the time of incubation. This has been identified as a potential source of error, since high affinity binders may have equilibration times of many hours [5, 6] and protocols with a few hours of incubation are still common.
An alternative to the assays described above is to monitor the ligand-receptor binding in real-time.
These measurements do not depend on equilibrium and further provides an inherent quality control, where assay problems can immediately be detected as irregularities in the binding curve. More importantly, time-resolved interaction measurements provide information about not only the affinity, but also the binding kinetics, i.e. the association and dissociation rates. This is particularly important during drug development, where it is crucial to know if the drug will have enough time to bind the target before it is cleared from the blood, and where the biological effect depends on residence time, i.e. how long a drug remains bound to its target [7] . Because of the information-rich nature of real-time interaction data, new tools have emerged to extract additional information from such data. One example is the analytical procedure Interaction Map, which can decipher the degree of interaction heterogeneity from time resolved binding traces, to understand if a molecule binds to its target in different manners [8] . Such heterogeneity can be caused by various conformations, molecular variants or dimer states and will affect the interaction kinetics, visible through Interaction Map.
So far most real-time interaction studies have been performed in cell free systems, using e.g. the sensitive and label-free technology of surface plasmon resonance (SPR) [9, 10] . However, these measurements are rarely straightforward due to difficulties in overexpression, purification and stabilization of the GPCRs [10, 11] . There may further be discrepancies between the SPR results and effects in living systems, due to the lack of G-protein and stabilizing membrane components. Similar observations have been made in other systems, where large differences between SPR data and cell data were observed [12] .
The aim of the present study was to establish a method for real-time measurements of interactions with GPCRs in living cells. This was conducted using the instrument LigandTracer®, which has been described in detail and validated previously for overexpressed receptors in cancer cells [13, 14] . In brief, adherent cells expressing the target protein are seeded in a local part of a circular Petri dish, which is placed on an inclined, rotating support with a detector positioned over the elevated part of the dish (Fig. 1 A) . A buffer containing a radiolabeled molecule, e.g. a peptide or protein, is added. If the molecule binds to the target on the cells, the detector will register a peak each time the cell area passes by the detector, using a cell-free area of the dish as a reference. By following the peak height over time, a real-time binding trace is obtained. The method was originally developed for a single cell area, but after further development at least three areas can be studied in parallel, enabling e.g.
comparison of binding to different cell lines (Fig. 1 B) .
*Position of Figure 1*
The use of living cells in time-resolved binding assays has the potential to improve understanding of GPCRs in their true environment. Two model systems were used to evaluate the method and demonstrate proof-of-concept. In the first study, the binding of the pPYY peptide to cells expressing different degrees of the human neuropeptide receptor hY2R [15] was measured. In the second study, the interaction between the bombesin antagonist RM26 developed for medicinal imaging of cancer and the gastrin-releasing peptide receptor GRPR [16] was detected. The binding showed clear signs of interaction heterogeneity and was therefore further evaluated using Interaction Map.
Material and methods

Reagents and labeling
The human peptide YY pre-labeled with 125 I (denoted 125 I-pPYY) was purchased from PerkinElmer (Product No. NEX240050UC, Waltham, MA, USA).
The bombesin antagonist analog denoted NOTA-PEG6-RM26 (NOTA-PEG6-D-Phe-Gln-Trp-Ala-Val-Gly-
, Leu14] bombesin) [17] was synthesized and labeled with 111 In (Covidien, Dublin, Ireland) as described previously [16] .
Cells
The human embryonic kidney 293 cell line (HEK-293) and the human prostate cancer cell line PC3
were used in this study. The cells were grown at 37 °C, 5% CO 2 , in DMEM (HEK-293) or RPMI (PC3) medium containing 10% (v/v) fetal calf serum and PEST (penicillin 100 IU/ml and streptomycin 100 µg/ml). Additionally, the DMEM medium used for the HEK-293 cells contained Amphotericin B (Life Technologies, Carlsbad, CA, USA) and the RPMI medium for PC3 contained L-Glutamine (2 mM, Biochrom Ag, Berlin, Germany).
Transfection for transient and stable protein expression of hY2R
The hY2R was inserted into a pcDNA-DEST47 expression vector. HEK-293 cells were transfected with the hY2R expression vectors using Lipofectamine 2000 and OPTI-MEM according to the instructions from the manufacturer. The same transfection procedure was used for the stable transfection. After 24 h transfection, cells with stable expression were selected using DMEM medium containing 500 µg/ml geneticin. All reagents for transfection were from Life Technologies (Carlsbad, CA, USA).
Real-time measurement of interactions with GPCR on cells in LigandTracer Grey
Approximately 1 million cells were seeded in Petri dishes (Cat. No. 172958, Nunc, Roskilde, Denmark)
at least two days before experimental day. All binding measurements were monitored in real-time on cells using LigandTracer Grey instruments (Ridgeview Instruments AB, Vänge, Sweden), essentially as described previously [12, 13, 18, 19, 20] .
The binding of 300 pM 125 I-pPYY to stably expressed hY2R on transfected HEK-293 cells was measured for 5-6 h. The labeled peptide was then replaced with fresh medium, and the dissociation was followed over-night. In another measurement, the binding of 900 pM 125 I-pPYY was monitored to stably hY2R-transfected HEK-293, transiently hY2R-transfected HEK-293 and wild-type HEK-293 simultaneously as shown in Figure 1 B.
The binding of 0.3 and 10 nM 111 In-NOTA-PEG6-RM26 was monitored for 2.5 and 1.5 h respectively, followed by a dissociation measurement over-night.
All measurements were conducted at room temperature. Corrections for nuclide decay (t 1/2 = 60 days for 125 I and t 1/2 = 2.8 days for 111 In) were done automatically in the software controlling the instrument.
Kinetic evaluation in TraceDrawer
Data was analyzed using TraceDrawer 1.5 (Ridgeview Instruments AB, Vänge, Sweden), by fitting the curves to the OneToOne kinetic model.
Estimation of interaction heterogeneity using Interaction Map
The heterogeneity of the data for GRPR was analyzed using the mathematical method Interaction Map (Ridgeview Diagnostics AB, Uppsala, Sweden), which has been validated for overexpressed surface receptors as thoroughly described thoroughly previously [8, 21] .
The main assumption of the method is that the binding of a molecule to a target can be expressed as a sum of monovalent interactions [22, 23] , each having a unique combination of association rate constant k a and dissociation rate constant k d , and a weighting parameter W describing the contribution to the measured curve.
This results in a two-dimensional distribution of k a and k d , representing the recognition and the stability of the complex, where each peak in this on-off like plot [24] corresponds to a contributing interaction of the measured curve.
Results
The interaction of 125 I-labeled pPYY with hY2R on HEK-293 cells was monitored continuously for 20 h.
After 5 h of incubation the signal continued to increase, meaning that equilibrium had not yet been reached (Fig. 2 A, black curve) . Upon removal of the peptide solution after 5.5 hours, the signal immediately started to decrease and most of the bound 125 I-pPYY dissociated from hY2R over the course of 15 h. The data fitted well to the one-to-one kinetic model, describing one type of molecule binding to one type of target (Fig. 2 A, grey curve) . According to the results of the curve fit, the interaction had an association rate constant, k a , of 5. and wild-type cells (Fig. 2 B, grey solid line) . The stable cell line produced the highest signal and the wild-type cells the lowest.
*Position of Figure 2*
In another series of experiments, increasing concentrations of the 111 In-labeled bombesin antagonist ( 111 In-NOTA-PEG6-RM26) were stepwise added to PC3 cells expressing GRPR (Fig. 3 A) . The association rate was relatively slow when 0.3 nM concentration was used, but quickly reached equilibrium with the higher concentration (10 nM). Judging from the dissociation part of the curve, the interaction contained a fast dissociation component, observed as a quick signal decrease after 111 In-NOTA-PEG6-RM26 had been removed, followed by a subsequent slower dissociating component. This type of interaction behavior resulted in a poor fit to the one-to-one kinetic model (data not shown), suggesting that the interaction is not homogenous and that more than one type of The interaction between 300 pM 125 I-pPYY and the transfected HEK-293 cells expressing hY2R was slow, with a time to equilibrium of more than five hours (Fig. 2 A) . Slow association rates of this kind must be taken into account when performing end-point assays, which typically require that equilibrium is reached. Too short incubation times will result in inaccurate data, increasing the risk of drawing invalid conclusions about the biological system. Using higher concentrations of the molecule in solution will speed up the interaction and may be an alternative to longer incubations.
When comparing the interaction of 125 I-pPYY to hY2R on wild-type HEK-293 cells and transfected HEK-293 cells, a weak binding to the wild-type cells was observed (Fig. 2 B) . This was likely an unspecific binding, as corroborated by the different curve shape of the wild-type cells. For the two transfected cell types, the signal continued to increase over many hours, similar to the data of Figure   2 A, but for the wild-type cells the signal rapidly increased and then remained relatively stable throughout the run.
There are different possible explanations to why two types of interactions were present for the bombesin analogue on PC3 cells (Fig. 3) . It is possible that the two interactions correspond to the antagonist binding different conformations of the GPCR. These conformations may be constantly present on the cell surface, or the result of a conformation change occurring after 111 In-NOTA-PEG6-RM26 has bound. In the latter case, one would expect that the association rate would be the same for both interactions (corresponding to the antagonist binding the inactive state) and that the different dissociation rates corresponds to 111 In-NOTA-PEG6-RM26 detaching from either the inactive or active state. Since the differences in association rates were rather small it is difficult to exclude either of the two hypotheses. Other explanations are also possible, such as post-translational modifications.
The use of real-time binding curves to understand interaction heterogeneity is relatively new, but
intriguing. This type of analysis may be particularly important for GPCRs, since the dynamics of the 25.2 ± 3.7
